Oleclumab Plus Chemotherapy Shows Promise in Metastatic Pancreatic Cancer
Key Insights
A Phase Ib/II trial evaluated oleclumab, with or without durvalumab, combined with chemotherapy in metastatic pancreatic ductal adenocarcinoma (search) (mPDAC (search)).
The combination of oleclumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS).
The study suggests oleclumab could offer a new treatment option for mPDAC (search), addressing a critical unmet need in this aggressive cancer.
A Phase Ib/II randomized clinical trial has revealed promising results for oleclumab, an anti-CD73 (search) antibody, when combined with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (search) (mPDAC (search)). The study, published in Clinical Cancer Research, investigated the efficacy and safety of oleclumab with or without durvalumab, an anti-PD-L1 antibody, plus chemotherapy (gemcitabine and nab-paclitaxel) in this challenging patient population.
The trial enrolled patients with previously untreated mPDAC (search) and randomized them to receive either oleclumab plus chemotherapy or chemotherapy alone. An exploratory arm also included durvalumab in combination with oleclumab and chemotherapy. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety.
The results indicated that the combination of oleclumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy alone. While the addition of durvalumab did not appear to provide additional benefit in this study, the oleclumab plus chemotherapy arm showed a hazard ratio (HR) that favored the experimental arm. Further details on the specific PFS and OS data will be crucial in interpreting the full clinical impact.
Pancreatic cancer remains one of the most lethal malignancies, with a 5-year survival rate of less than 10%. Metastatic pancreatic cancer is even more difficult to treat, and new therapeutic options are urgently needed. The current standard of care typically involves chemotherapy regimens, but these often provide limited benefit and are associated with significant toxicities. Immunotherapy has shown limited success in pancreatic cancer, highlighting the need for novel approaches.
Oleclumab targets CD73 (search), an enzyme that converts adenosine monophosphate (AMP) to adenosine in the tumor microenvironment. Adenosine can suppress immune responses and promote tumor growth. By blocking CD73, oleclumab aims to enhance anti-tumor immunity and improve the efficacy of chemotherapy. This mechanism of action provides a rationale for combining oleclumab with chemotherapy and potentially other immunotherapeutic agents.
According to the study publication, "A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (search)" suggests that oleclumab could offer a new treatment option for mPDAC (search), addressing a critical unmet need in this aggressive cancer. Further research is warranted to confirm these findings and explore the full potential of oleclumab in pancreatic cancer treatment.